BGPT: Author Review: Ramin Shiekhattar

Fuel Your Discoveries

Quick Explanation Copied

Author scientific strength check (Ramin Shiekhattar)

Research impact appears strong: OpenAlex match shown with h-index ~72 and ~36,530 citations (but note: author disambiguation collisions can happen, so treat as a signal, not proof).
Publication signals align with high-impact molecular biology (e.g., major mechanistic papers on microRNA biogenesis and chromatin regulation).
Evidence quality looks heterogeneous across domains: the provided raw-data examples include deep mechanistic work plus omics-heavy studies (best assessed by looking at causality, controls, and in vivo support, not just occupancy/activity).

If you want, tell me which of the author’s papers you care about most (epigenetics vs miRNA vs DNA repair), and I’ll critique the specific figures/methods (not abstracts) and extract falsifiable failure modes.

Long Explanation

Ramin Shiekhattar — Critical scientific author review

Date context: April 09, 2026. Scope: your prompt provides (i) author-level citation metrics (OpenAlex + your “Author Citation Information”), and (ii) raw-data extraction snippets for several specific papers (with DOIs, methods, limitations, and quality scores). I critique what is known vs inferred and call out uncertainty + likely failure modes in the evidence you supplied.

1) Citation-metric signal (from your provided OpenAlex summary)

These are author-level metadata signals, not direct proof of experimental rigor; they can be distorted by name disambiguation and field-average citation inflation. Treat as triage.

2) Provided “paper quality scores” across the extracted raw-data set

Your dataset includes per-paper scalar scores (e.g., paper_scientific_quality_score, paper_reproducibility_score, etc.). I visualize only those provided values—no new assumptions.

Sketched interpretation (strictly from your extraction fields):

The SNAPC1 genome-wide occupancy/responsiveness study is scored very highly across scientific quality (9) and reproducibility (9) in the provided extraction for 10.1128/MCB.00906-12 .
The KDM7/PHD-related piece is a review-style synthesis in the extraction and thus its “reproducibility” is less directly comparable to primary experimental studies; it includes crystallography and biochemical/ChIP-seq evidence as described .

3) Evidence modality map (from your extracted methods/experiments)

This is a methods-content visualization built only from the “methods_and_experimental_techniques” strings in your raw-data snippets.

4) Scientific strength review (what the evidence supports vs what remains uncertain)

A. Mechanistic epigenetics / chromatin logic

The provided review excerpt argues that KDM7 enzymes (PHF2/PHF8/KIAA1718) use PHD “plant homeodomain” recognition of H3K4me3 to position the JmjC catalytic domain and promote transcriptional activation by removing repressive histone marks; the extraction also states overlapping vs distinct substrate preferences and a disease link via PHF8 mutations . Strengths suggested by the provided extraction: multi-modal convergence (structure + binding + biochemical + chromatin occupancy) is more persuasive than any single modality. Critical blindspots / failure modes (explicitly flagged in the extraction): (i) overreliance on in vitro assays and overexpression, (ii) partial in vivo validation across family members, (iii) possible species-specific differences, and (iv) extrapolation risk from domain-level structural work to full-length enzyme behavior .

B. Genome-wide transcription factor occupancy & functional responsiveness

The SNAPC1 study in the provided raw-data snippet is strongly aligned with “causal-ish” claims rather than pure correlation: it includes ChIP-seq occupancy mapping of SNAPC1/SNAPC4 and RNAPII, perturbation using shRNA knockdown, and functional readouts via EGF and retinoic acid stimulation; importantly, the extraction states ChIP-seq data are deposited to GEO (GSE37403) . What is known (from extraction): SNAPC1 occupancy extends beyond UsnRNA genes to a broader set of protein-coding genes, co-varies with RNAPII elongation dynamics, and knockdown reduces signal-responsive transcription . What remains uncertain: ChIP-seq occupancy is not direct proof of all downstream functional steps; off-target effects of shRNA are a generic risk; and cell-line-specific generalization limits are described in the extraction .

C. Protein complex biochemistry & DNA repair relevance

Your third extracted snippet describes a study on BRCC, a complex containing BRCA1 and BRCA2 and its role in DNA repair/cell-cycle response to damage. It reports biochemical characterization methods (gel filtration, SDS-PAGE, immunoprecipitation, mass spectrometry) and a functional role in DNA damage response, with described implications for understanding breast cancer mechanisms . Critical note: in your provided extraction, many scoring fields like reproducibility/general usefulness are missing (set to “not provided” in your data). Therefore I do not over-interpret rigor from this one snippet alone. Likely blindspots noted in extraction: cell-line representativeness and selection of patient/tumor specimens (if used), and that the assay repertoire may miss additional mechanistic branches of BRCC biology .

D. Epigenetic-therapy-adjacent mechanistic translational work (from your provided AML preprint snippet)

Your provided raw-data snippet for an AML study (preprint DOI shown) describes dual LSD1/HDAC inhibition in combination with ATRA to promote differentiation/apoptosis, along with mechanistic claims about displacing CoREST/LSD1 and recruiting P300, widening H3K4me2 domains, increasing chromatin accessibility, and increasing RA-responsive transcription . Critical skepticism: translational claims that read like treatment efficacy require careful scrutiny of (i) off-target effects of inhibitors, (ii) cell-line selection and generalizability, (iii) whether causality is directly demonstrated for the proposed chromatin changes, and (iv) absence of in vivo validation in the provided text; your extraction explicitly mentions these kinds of limitations .

5) Overall scientific strength assessment (based only on the evidence you supplied)

High-confidence signals (supported by your snippets):

Methodological coverage: the provided excerpts include both structural/biochemical characterization (e.g., crystallography + demethylation logic in the KDM7 review) and genome-wide occupancy/function perturbation logic (SNAPC1 study with GEO deposition) .
Explicit limitation awareness: each snippet you supplied includes stated limitations (mapping biases/off-targets/causality gaps in SNAPC1; domain-level-to-full-length uncertainty and overreliance on in vitro systems in the KDM7 review; cell-line representativeness/assay scope in BRCC; and generalizability/off-target/in vivo absence in the AML preprint) .

Key uncertainty / why a single-number “rigor” score is risky:

Your supplied set mixes reviews, primary mechanistic papers, and an omics-heavy translational preprint. Comparing rigor across these requires checking the actual experimental controls, replicate structure, and causal perturbation evidence in each paper’s full text/figures (not included fully here) .
Some extracted scoring fields are missing for at least one paper (https://dx.doi.org/10.1016/s1097-2765(03)00424-6), so the provided scalar summaries can’t fully cover rigor/reproducibility uncertainty .

Most testable falsification angles (from your extraction “how_to_falsify” fields):

KDM7/PHD logic can be falsified if PHD–H3K4me3 binding is dispensable for transcriptional activation, if catalytic activity is dispensable, if localization contradicts predicted promoter mark targeting, or if separating binding vs catalysis mutants still rescue transcription .
SNAPC1 coactivator/elongation-responsiveness can be falsified if SNAPC1 perturbation does not affect RNAPII elongation occupancy dynamics and signal-induced transcriptional activation .

6) Drill-down actions on BGPT

Feedback:

Updated: April 10, 2026